

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM713247

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Xeris Pharmaceuticals, Inc.		03/08/2022	Corporation: DELAWARE
StrongBridge Dublin Limited		03/08/2022	Private Limited Company: IRELAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Hayfin Services LLP		
<b>Street Address:</b>	One Eagle Place		
<b>City:</b>	London		
<b>State/Country:</b>	UNITED KINGDOM		
<b>Postal Code:</b>	SW1Y 6AF		
<b>Entity Type:</b>	Limited Liability Partnership: ENGLAND AND WALES		
<b>PROPERTY NUMBERS Total: 6</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5237588	STRONGBRIDGE BIOPHARMA	
<b>Registration Number:</b>	5851851	RECORLEV	
<b>Registration Number:</b>	5869431		
<b>Registration Number:</b>	5771696	RIDE FOR RARE DISEASES	
<b>Serial Number:</b>	90663225	REGCORLEV	
<b>Serial Number:</b>	90663231	ZIBCORLEV	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	800-494-5225		
<b>Email:</b>	ipteam@cogencyglobal.com		
<b>Correspondent Name:</b>	Stewart Walsh		
<b>Address Line 1:</b>	1025 Connecticut Ave NW, Suite 712		
<b>Address Line 2:</b>	COGENCY GLOBAL Inc.		
<b>Address Line 4:</b>	Washington, D.C. 20036		
<b>ATTORNEY DOCKET NUMBER:</b>	1618821 TM IPSA		
<b>NAME OF SUBMITTER:</b>	Monet Zaccarelli		

OP \$165.00 5237588

<b>SIGNATURE:</b>	/Monet Zaccarelli/
<b>DATE SIGNED:</b>	03/09/2022
<b>Total Attachments: 10</b> source=Xeris - Trademark Security Agreement#page1.tif source=Xeris - Trademark Security Agreement#page2.tif source=Xeris - Trademark Security Agreement#page3.tif source=Xeris - Trademark Security Agreement#page4.tif source=Xeris - Trademark Security Agreement#page5.tif source=Xeris - Trademark Security Agreement#page6.tif source=Xeris - Trademark Security Agreement#page7.tif source=Xeris - Trademark Security Agreement#page8.tif source=Xeris - Trademark Security Agreement#page9.tif source=Xeris - Trademark Security Agreement#page10.tif	

## TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT, dated as of March 8, 2022 (this “*Trademark Security Agreement*”), made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “*Trademark Grantors*”), is in favor of Hayfin Services LLP, as administrative agent for the Secured Parties (in such capacity, together with its successors and assigns, the “*Agent*”).

### W I T N E S S E T H:

WHEREAS, the Trademark Grantors are party to a Security Agreement, dated as March 8, 2022 (as amended, amended and restated, supplemented, renewed, extended or otherwise modified from time to time, the “*Security Agreement*”) in favor of the Agent, pursuant to which the Trademark Grantors are required to execute and deliver this Trademark Security Agreement (capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Security Agreement);

WHEREAS, pursuant to the terms of the Security Agreement, each Trademark Grantor has created in favor of the Agent a security interest in, and the Agent has become a secured creditor with respect to, the Trademark Collateral (as defined below);

NOW, THEREFORE, in consideration of the premises and to induce the Agent and the Lender to enter into the Credit Agreement and to induce the Lender to make their respective extensions of credit to the Borrower thereunder, each Trademark Grantor hereby grants to the Agent, for the ratable benefit of the Secured Parties, a security interest in all of the following property now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “*Trademark Collateral*”), as collateral security for the complete payment and performance when due (whether at the stated maturity, by acceleration or otherwise) of all Secured Obligations:

(a) all Trademarks of such Trademark Grantor, including, without limitation, the registered and applied-for Trademarks of such Grantor listed on **Schedule 1** attached hereto (excluding any application for registration of a trademark filed on an intent-to-use (or equivalent) basis solely to the extent that the grant of a security interest in any such trademark application would materially adversely affect the validity or enforceability of such application or the resulting registration, or result in abandonment of application or cancellation of the resulting registration);

(b) to the extent not covered by **clause (a)**, all Proceeds of any of the foregoing;

(c) to the extent not covered by **clause (a)**, the goodwill of the businesses with which the Trademarks are associated; and

(d) to the extent not covered by **clause (a)**, all causes of action arising prior to or after the date hereof for infringement of any of the Trademarks or unfair competition regarding the same.

The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Agent pursuant to the Security Agreement, and the Trademark Grantors hereby acknowledge and affirm that the rights and remedies of the Agent with respect to the security interest in the Trademarks made and granted hereby are more fully set forth in the Security Agreement. In the event that any provision of this Trademark Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

Each Trademark Grantor hereby authorizes and requests that the Commissioner of Patents and Trademarks record this Trademark Security Agreement.

**THIS TRADEMARK SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS TRADEMARK SECURITY AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.**

This Trademark Security Agreement may be executed by one or more of the parties to this Trademark Security Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Trademark Security Agreement by facsimile transmission or electronic transmission (in PDF format) shall be effective as delivery of a manually executed counterpart hereof.

*[Signature Pages Follow]*

IN WITNESS WHEREOF, the parties hereto have duly executed this Trademark Security Agreement as of the date first above written.

GRANTORS:

**XERIS PHARMACEUTICALS, INC.**

DocuSigned by:  
By Steve M. Pieper  
A24856319594470...  
Name: Steven M. Pieper  
Title: Chief Financial Officer

**STRONGBRIDGE DUBLIN LIMITED**

DocuSigned by:  
By Steve M. Pieper  
A24856319594470...  
Name: Steven M. Pieper  
Title: Board Member

Accepted and Agreed:  
**HAYFIN SERVICES LLP**

By \_\_\_\_\_  
Name: Vikas Mehta  
Title: Authorized signatory

Address for Notices:  
One Eagle Place  
London, SW1Y 6AF  
Email: Andrew.Merrill@hayfin.com  
Michael.Tischler@hayfin.com  
gc@hayfin.com  
Tel: +44 207 074 2900  
Attention: Nicola O'Regan, Andrew Merrill, Michael Tischler, Legal Team / Loan Operations

With a copy (which shall not constitute notice) to:  
Morrison & Foerster LLP  
250 West 55th Street  
New York, NY 10019  
Attn: Mark S. Wojciechowski  
Tel.: (212) 468 - 8079  
Email: MWojciechowski@mfo.com

**TRADEMARKS**Trademark Registrations and Applications**Xeris Pharmaceuticals Trademarks/Applications**

<b>Mark</b>	<b>Country</b>	<b>Appl. No.</b>	<b>Appl. Date</b>	<b>Reg. No.</b>	<b>Reg. Date</b>
GLUCAXER	EUROPEAN UNION	017884655	4/06/2018	017884655	08/29/2018
GLUCAXER	UNITED KINGDOM	UK0091788 4655	4/6/2018	UK0091788 4655	8/29/2018
GLUCAXER HYOPEN	EUROPEAN UNION	017884652	4/6/2018	017884652	8/29/2018
GLUCAXER HYOPEN	UNITED KINGDOM	UK0091788 4652	4/6/2018	UK0091788 4652	8/29/2018
GVOKE	USA	88/011,935	6/22/2018	6,019,623	3/24/2020
GVOKE	ARGENTINA	3767595	12/20/2018	(Pending)	(Pending)
GVOKE	ARGENTINA	3767594	12/20/2018	(Pending)	(Pending)
GVOKE	AUSTRALIA	2004108	12/19/2018	1462300	12/19/2018
GVOKE	BRAZIL	916491285	12/21/2018	916491285	9/17/2019
GVOKE	BRAZIL	916491331	12/21/2018	916491331	9/17/2019
GVOKE	CANADA	1,936,992	12/19/2018	(Pending)	(Pending)
GVOKE	SWITZERLAND	1462300	12/19/2018	1462300	12/19/2018
GVOKE	CHINA	1462300	12/19/2018	1462300	12/19/2018
GVOKE	EUROPEAN UNION	1462300	12/19/2018	1462300	12/19/2018
GVOKE	UNITED KINGDOM	UK0080146 2300	12/19/2018	UK0080146 2300	12/19/2018
GVOKE	WIPO	A0081866	12/19/2018	1462300	12/19/2018
GVOKE	ISRAEL	316074	12/19/2018	1462300	12/19/2018
GVOKE	INDIA	4157240	12/19/2018	1462300	12/19/2018

GVOKE	JAPAN	1462300	12/19/2018	1462300	12/19/2018
GVOKE	SOUTH KOREA	1462300	12/19/2018	1462300	12/19/2018
GVOKE	MEXICO	1462300	12/19/2018	2249278	12/19/2018
GVOKE	NORWAY	1462300	12/19/2018	1462300	12/19/2018
GVOKE	NEW ZEALAND	1118946	12/19/2018	1462300	12/19/2018
GVOKE	RUSSIAN FEDERATION	1462300	12/19/2018	1462300	12/19/2018
GVOKE	SOUTH AFRICA	2018/38079	12/19/2018	2018/38079	12/19/2018
GVOKE	SOUTH AFRICA	2018/38080	12/19/2018	2018/38080	12/19/2018
GVOKE HYOPEN	USA	88/011,932	6/22/2018	6,136,874	8/25/2020
GVOKE HYOPEN	ARGENTINA	3767592	12/20/2018	(Pending)	(Pending)
GVOKE HYOPEN	ARGENTINA	3767593	12/20/2018	(Pending)	(Pending)
GVOKE HYOPEN	AUSTRALIA	2004049	12/19/2018	1462159	12/19/2018
GVOKE HYOPEN	BRAZIL	916491374	12/21/2018	916491374	9/17/2019
GVOKE HYOPEN	BRAZIL	916491412	12/21/2018	916491412	9/17/2019
GVOKE HYOPEN	CANADA	1,936,993	12/19/2018	(Pending)	(Pending)
GVOKE HYOPEN	SWITZERLAND	1462159	12/19/2018	1462159	12/19/2018
GVOKE HYOPEN	CHINA	1462159	12/19/2018	1462159	12/19/2018
GVOKE HYOPEN	EUROPEAN UNION	1462159	12/19/2018	1462159	12/19/2018
GVOKE HYOPEN	UNITED KINGDOM	UK0080146 2159	12/19/2018	UK0080146 2159	12/19/2018
GVOKE HYOPEN	WIPO	1462159	12/19/2018	1462159	12/19/2018



GVOKE HYPOPEN	ISRAEL	316062	12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	INDAI	4157397	12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	JAPAN	1462159	12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	SOUTH KOREA	40-2020- 0063013	12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	MEXICO	1462159	12/19/2018	2249277	12/19/2018
GVOKE HYPOPEN	NORWAY	1462159	12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	NEW ZEALAND	1118922	12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	RUSSIAN FEDERATION	1462159	12/19/2018	1462159	12/19/2018
GVOKE HYPOPEN	SOUTH AFRICA	2018/38081	12/19/2018	2018/38081	10/5/2020
GVOKE HYPOPEN	SOUTH AFRICA	2018/38082	12/19/2018	2018/38082	10/5/2020
HYPOPEN	USA	87/582,219	8/24/2017	6,169,709	10/6/2020
HYPOPEN	EUROPEAN UNION	017923552	6/27/2018	017923552	11/29/2018
HYPOPEN	UNITED KINGDOM	UK0091792 3552	6/27/2018	UK0091792 3552	11/29/2018
XERIJECT	USA	90/359,515	12/4/2020	(Pending)	(Pending)
XERIJECT	AUSTRALIA	2203736	6/3/2021	1608546	6/3/2021
XERIJECT	CANADA	2,128,132	6/3/2021	(Pending)	(Pending)
XERIJECT	CHINA	1608546	6/3/2021	1608546	02/18/2022
XERIJECT	EUROPEAN UNION	017459199	11/10/2017	017459199	3/12/2018
XERIJECT	UNITED KINGDOM	UK0091745 9199	11/10/2017	UK0091745 9199	3/12/2018
XERIJECT	WIPO	A0109570	6/3/2021	1608546	6/3/2021

XERIJECT	JAPAN	1608546	6/3/2021	(Pending)	(Pending)
XERIJECT	SOUTH KOREA	1608546	6/3/2021	(Pending)	(Pending)
XERIJECT	MEXICO	1608546	6/3/2021	(Pending)	(Pending)
XERIJECT	MEXICO	1608546	6/3/2021	(Pending)	(Pending)
XERIS PHARMACEU TICALS	USA	87/450,239	5/15/2017	6,059,089	5/19/2020
XERIS PHARMACEU TICALS	USA	87/452,737	5/17/2017	5,364,202	12/26/2017
XERISOL	USA	90/359,499	12/4/2020	(Pending)	(Pending)
XERISOL	AUSTRALIA	2201871	6/3/2021	1606899	6/3/2021
XERISOL	CANADA	1606899	6/3/2021	(Pending)	(Pending)
XERISOL	CHINA	1606899	6/3/2021	1606899	6/3/2021
XERISOL	EUROPEAN UNION	017459173	11/10/2017	017459173	3/12/2018
XERISOL	UNITED KINGDOM	UK0091745 9173	11/10/2017	UK0091745 9173	3/12/2018
XERISOL	WIPO	A0109571	6/3/2021	1606899	6/3/2021
XERISOL	JAPAN	1606899	6/3/2021	(Pending)	(Pending)
XERISOL	SOUTH KOREA	1606899	6/3/2021	(Pending)	(Pending)
XERISOL	MEXICO	1606899	6/3/2021	(Pending)	(Pending)
XERISOL	MEXICO	1606899	6/3/2021	(Pending)	(Pending)
GVOKE (logo)	USA	90/165,932	9/8/2020	(Pending)	(Pending)
GVOKE (logo)	CANADA	1607372	3/5/2021	(Pending)	(Pending)
GVOKE (logo)	WIPO	A0106151	3/5/2021	1607372	3/5/2021
GVOKE (logo)	ISRAEL	1607372	3/5/2021	(Pending)	(Pending)
GVOKE (logo)	MEXICO	1607372	3/5/2021	(Pending)	(Pending)
GVOKE (logo)	MEXICO	1607372	3/5/2021	(Pending)	(Pending)

II. Strongbridge Dublin Ltd./Strongbridge US Trademarks/Applications

Mark/Owner	Country/Number	Status
<b>OGLUO</b>  <b>Strongbridge Dublin Limited</b>	European Union- 018288558  United Kingdom- 3521904	Registered
<b>NORMOCORT</b>  <i>Cortendo AB</i>	Europe - CTM 010869048	Registered
<b>STRONGBRIDGE BIOPHARMA</b>  <i>Strongbridge Dublin Ltd.</i>	WO 1279854	Registered
	US 5,237,588	Registered
	Australia 1279854	Registered
	China 1279854	Registered
	Europe - CTM 1279854	Registered
	Israel 1279854	Registered
	India 1279854	Registered
	Japan 1279854	Registered
	Mexico 1279854	Pending
	Turkey 1279854	Registered
	Brazil 910544115	Registered
	Canada 1741329	Registered
<b>CORYNTHIA</b>  <i>Strongbridge Dublin Ltd.</i>	Brazil 910758875	Registered
	Canada 1054053	Registered
	WO 1297646	Registered

<b>RECORLEV</b> <i>Strongbridge Dublin Ltd.</i>	US 5,851,851	Registered
	Canada 1069362	Registered
	Brazil 911007903	Registered
	Australia 1297646	Registered
	China 1297646	Registered
	Europe - CTM 1297646	Registered
	Israel 1297646	Registered
	India 1297646	Registered
	Japan 1297646	Registered
	Mexico 1297646	Registered
	Turkey 1297646	Registered
<b>REGCORLEV</b> <i>Strongbridge Dublin Ltd.</i>	US 90/663,225	Pending
<b>ZIBCORLEV</b> <i>Strongbridge Dublin Ltd.</i>	US 90/663,231	Pending
<b>BICYCLE DESIGN</b> <i>Strongbridge US Inc.</i>	US 5,869,431	Registered
<b>RIDE FOR RARE DISEASES</b> <i>Strongbridge US Inc.</i>	US 5,771,696	Registered